Quanterix (QTRX) Competitors

In the previous week, Quanterix had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 5 mentions for Quanterix and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.67 beat Quanterix's score of 0.38 indicating that Mesa Laboratories is being referred to more favorably in the media.

Mesa Laboratories has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Mesa Laboratories has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Mesa Laboratories has a net margin of 2.69% compared to Quanterix's net margin of -71.86%. Mesa Laboratories' return on equity of 20.96% beat Quanterix's return on equity.

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mesa Laboratories presently has a consensus target price of $94.00, indicating a potential downside of 7.78%. Quanterix has a consensus target price of $4.00, indicating a potential upside of 65.29%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Mesa Laboratories.

Cytek Biosciences has a net margin of -38.98% compared to Quanterix's net margin of -71.86%. Cytek Biosciences' return on equity of -12.40% beat Quanterix's return on equity.

Quanterix has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Quanterix presently has a consensus price target of $4.00, suggesting a potential upside of 65.29%. Cytek Biosciences has a consensus price target of $5.56, suggesting a potential upside of 21.06%. Given Quanterix's higher possible upside, equities analysts plainly believe Quanterix is more favorable than Cytek Biosciences.

Cytek Biosciences has higher revenue and earnings than Quanterix. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

In the previous week, Cytek Biosciences had 4 more articles in the media than Quanterix. MarketBeat recorded 9 mentions for Cytek Biosciences and 5 mentions for Quanterix. Cytek Biosciences' average media sentiment score of 0.52 beat Quanterix's score of 0.38 indicating that Cytek Biosciences is being referred to more favorably in the news media.

86.5% of Quanterix shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quanterix has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

Quanterix has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

86.5% of Quanterix shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 1.5% of Quanterix shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Ginkgo Bioworks had 5 more articles in the media than Quanterix. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 5 mentions for Quanterix. Quanterix's average media sentiment score of 0.38 beat Ginkgo Bioworks' score of 0.37 indicating that Quanterix is being referred to more favorably in the media.

Quanterix has a net margin of -71.86% compared to Ginkgo Bioworks' net margin of -259.96%. Quanterix's return on equity of -23.92% beat Ginkgo Bioworks' return on equity.

Quanterix currently has a consensus target price of $4.00, suggesting a potential upside of 65.29%. Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential downside of 9.00%. Given Quanterix's stronger consensus rating and higher probable upside, equities research analysts clearly believe Quanterix is more favorable than Ginkgo Bioworks.

Quanterix has a net margin of -71.86% compared to Pacific Biosciences of California's net margin of -82.49%. Quanterix's return on equity of -23.92% beat Pacific Biosciences of California's return on equity.

Quanterix presently has a consensus price target of $4.00, suggesting a potential upside of 65.29%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 60.12%. Given Quanterix's higher possible upside, equities research analysts clearly believe Quanterix is more favorable than Pacific Biosciences of California.

Quanterix has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quanterix has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 12 more articles in the media than Quanterix. MarketBeat recorded 17 mentions for Pacific Biosciences of California and 5 mentions for Quanterix. Quanterix's average media sentiment score of 0.38 beat Pacific Biosciences of California's score of -0.29 indicating that Quanterix is being referred to more favorably in the media.